Anti-Obesity Medications Market By Drug Class (GLP-1 Receptor Agonists, Sympathomimetic Appetite Suppressants, Lipase Inhibitors, Combination Therapies, Metabolism Boosters, Others), By Route of Administration (Oral, Injectable, Transdermal), By Application (Obesity Treatment, Weight Management & Control, Metabolic Syndrome Treatment, Bariatric Surgery Support, Other), By End-user (Hospitals & Clinics, Homecare Settings, Weight Management & Wellness Centers, Retail Pharmacies & Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• GLP-1 Receptor Agonists
• Sympathomimetic Appetite Suppressants
• Lipase Inhibitors
• Combination Therapies
• Metabolism Boosters
• Others

By Route of Administration

• Oral
• Injectable
• Transdermal

By Application

• Obesity Treatment
• Weight Management & Control
• Metabolic Syndrome Treatment
• Bariatric Surgery Support
• Other

By End-User

• Hospitals & Clinics
• Homecare Settings
• Weight Management & Wellness Centers
• Retail Pharmacies & Online Pharmacies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• AbbVie Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Sanofi S.A.
• Novo Nordisk
• Amgen Inc.
• Biogen Inc.
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited